Condition: B-cell Acute Lymphoblastic Leukemia (B-ALL) · Chronic Lymphocytic Leukemia (CLL) · B-cell Non-Hodgkin's Lymphoma (B-NHL) · Sponsor: Grit Biotechnology
The goal of this clinical study is to evaluate the safety and efficacy of GT801 injection in adult patients with relapsed/refractory CD19-positive B-cell hematologic malignancies and autoimmune hemolytic anemia. Interim analysis conducted when 2 patients complete primary endpoint measurement.
This description comes directly from the study's public registry record.
Dehui Zou · +8613602100955 · zoudehui@ihcams.ac.cn
Always discuss trial participation with your own doctor first.
| Zhengzhou Yihe Hospital | Zhengzhou, Henan, China | Active Not Recruiting |
| Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07205315